AOD-9604
AOD-9604 took the most extensive human-trial path of any compound referenced on this site — six trials, over 900 participants — and still fell short of its pivotal endpoint, making it a useful case study in rigorous but ultimately unsuccessful drug development.
Not currently stocked by KYIN Peptides, but available to order — see availability below.
What Is AOD-9604?
AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone (hGH 176-191), engineered to isolate HGH's lipolytic (fat-metabolizing) activity from its growth-promoting and insulin-desensitizing effects. It represents a different design approach from the receptor-agonist and mitochondrial-signaling compounds in KYIN's catalogue: rather than activating a receptor pathway, it is a truncated fragment of an existing hormone.
Research Focus
AOD-9604 sits alongside Retatrutide, MOTS-c, and 5-Amino-1MQ in KYIN's Weight Loss & Metabolic research, though its hormone-fragment design approach is distinct from all three. See our Weight Loss & Metabolic research overview for how it fits alongside KYIN's stocked metabolic peptides, or how Humanin compares as another non-stocked compound in this category.
Clinical & Preclinical Trial Data
Development was more extensive than most research peptides — Metabolic Pharmaceuticals ran six human trials in over 900 participants — but ultimately unsuccessful. A 12-week Phase IIa trial (300 participants) showed a modest weight-loss edge over placebo (2.6kg versus 0.8kg), but the pivotal 24-week Phase IIb trial (536 participants) found no statistically significant difference from placebo, and the obesity development program was discontinued in 2007.
Availability
AOD-9604 is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.
AOD-9604 questions
What is AOD-9604?
AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone (hGH 176-191), engineered to isolate HGH's lipolytic (fat-metabolizing) activity from its growth-promoting and insulin-desensitizing effects. Unlike receptor-agonist or mitochondrial-signaling compounds, it is a truncated fragment of an existing hormone.
How much human trial data exists for AOD-9604?
More than most research peptides — Metabolic Pharmaceuticals ran six human trials in over 900 participants — but development was ultimately unsuccessful. A 12-week Phase IIa trial (300 participants) showed a modest weight-loss edge over placebo, but the pivotal 24-week Phase IIb trial (536 participants) found no statistically significant difference from placebo, and the obesity development program was discontinued in 2007.
Does KYIN Peptides sell AOD-9604?
Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.
Interested in sourcing AOD-9604?
Contact us and we'll help you source it, or browse our stocked metabolic-focused peptides.